-
Legend Biotech’s Carvykti Files for European Approval as Second-Line MM Treatment
•
GenScipt Biotech Corp. (HKG: 1548), a China-based Contract Development and Manufacturing Organization (CDMO), through its subsidiary Legend Biotech Corporation (NASDAQ: LEGN), has announced a market approval filing in Europe for its chimeric antigen receptor (CAR)-T therapy Carvykti (ciltacabtagene autoleucel). The therapy is proposed as a second-line treatment for recurrent/refractory (R/R)…
-
GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies
•
GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced that the closing conditions for a licensing agreement between its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), and the Swiss pharmaceutical giant Novartis AG (NYSE: NVS) have been met. The agreement, initially revealed in November 2023,…
